Last update 08 May 2025

Yamanouchi Pharmaceutical Co. Ltd. /Over-the-Counter Phar Bus

Private Company|Tokyo-to, Japan

Overview

Related

25
Drugs associated with Yamanouchi Pharmaceutical Co. Ltd. /Over-the-Counter Phar Bus
YM-022
Target
CCKB
Mechanism
CCKB antagonists
Active Org.
Yamanouchi Pharmaceutical Co., Ltd.
Originator Org.
Astellas Pharma, Inc.Astellas Pharma, Inc.
Active Indication
Hyperchlorhydria
Inactive Indication
Pain [+1]
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
Tadocizumab
Target
GP IIb/IIIa
Mechanism
GP IIb/IIIa antagonists
Active Org.-
Originator Org.
Astellas Pharma, Inc.Astellas Pharma, Inc.
Active Indication-
Inactive Indication
Coronary Restenosis [+1]
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
YM-750
Target
ACAT1
Mechanism
ACAT1 inhibitors
Active Org.-
Originator Org.
Astellas Pharma, Inc.Astellas Pharma, Inc.
Active Indication-
Inactive Indication
Hyperlipidemias
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Yamanouchi Pharmaceutical Co. Ltd. /Over-the-Counter Phar Bus
Login to view more data
0 Patents (Medical) associated with Yamanouchi Pharmaceutical Co. Ltd. /Over-the-Counter Phar Bus
Login to view more data
100 Deals associated with Yamanouchi Pharmaceutical Co. Ltd. /Over-the-Counter Phar Bus
Login to view more data
100 Translational Medicine associated with Yamanouchi Pharmaceutical Co. Ltd. /Over-the-Counter Phar Bus
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Other
25
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
YM-264
 ( PAF receptor )		Asthma
More
Discontinued
YM-440
 ( PPARγ )		Diabetes Mellitus, Type 2
More
Discontinued
YM-750
 ( ACAT1 )		Hyperlipidemias
More
Discontinued
Nocloprost
 ( PGE2 )		Peptic Ulcer
More
Discontinued
YM-022
 ( CCKB )		Peptic Ulcer
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free